Review




Structured Review

Proteintech ihc
Ihc, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc/MEOX2+Antibody/pmc12969010-181-1-11
Average 93 stars, based on 6 article reviews
ihc - by Bioz Stars, 2026-10
93/100 stars

Images

Related Articles

other:

Article Title: CircEif3c/miR-96–5p/PHF20L1/MEOX2 axis in perivascular preadipocyte exosomes mediates fibroblast dysfunction and vascular remodeling
Article Snippet: For IHC, sections were incubated with primary antibodies (anti-MEOX2 1:500 #12449-1-AP, Proteintech) and (anti-Bcl-2, 1:100, ab194583; anti-PHF20L1, 1:100, ab118190; anti-Bax, 1:250, ab32503; anti-Bak, 1:200, ab104124), all Abcam at 37 °C (90 min), followed by HRP-secondary antibody (1:3000, AS003, ABclonal; 30 min), DAB staining (15 min, dark environment), and hematoxylin counterstaining (10 min).

Article Title: Integrative Multi-Analysis Identifies METTL3-Regulated FGF19 and H6PD as Candidate Targets in Diabetic Cognitive Impairment
Article Snippet: The following antibodies were used in this study: anti-GAPDH (Affinity BiosciencesCincinnati, OH, USA) (1:1000), anti-m 6 A (Synaptic Systems, Göttingen, Germany, 202003) (for Dot blot:1:1000, for IHC: 1:500), anti-METTL3 (15073-1-AP, Proteintech, Rosemont, Illinois, USA) (for WB:1:2000, for IHC: 1:750), anti-METTL14 (HPA038002, Sigma-Aldrich, St. Louis, MO, USA) (for WB:1:2000, for IHC: 1:1000), anti-WTAP (60188-1-Ig, Proteintech) (for WB:1:2000, for IHC: 1:500), FTO (27226-1-AP, Proteintech) (for WB:1:1000, for IHC: 1:400), ALKBH5 (16837-1-AP, Proteintech) (for WB:1:2000, for IHC: 1:200), Goat Anti-Mouse IgG H&L (HRP, Affinity Biosciences) (1:10000), Goat Anti-Rabbit IgG H&L (HRP, Affinity Biosciences, Cincinnati, OH, USA) (1:10000), and Goat Anti-Rabbit IgG H&L (Alexa Fluor 488, Abcam, Cambridge, UK) (1:500).

Article Title: TIMM23-ERAL1 Axis: A novel regulator of mitochondrial apoptosis in hepatocellular carcinoma.
Article Snippet: Hepatocellular carcinoma (HCC) is a highly aggressive malignancy of the digestive system characterized by increasing global incidence and mortality rates.. Translocase of the Inner Mitochondrial Membrane 23 (TIMM23), a key component of the mitochondrial inner membrane translocase complex, plays a critical role in the import and localization of mitochondrial proteins.. Elevated TIMM23 expression is significantly associated with poor prognosis in patients with HCC Conversely, TIMM23 downregulation was found to have induced apoptosis and significantly inhibited the proliferation, migration, and invasive potential of HCC cells both in vitro and in vivo.

Article Title: Integrative Multi-Analysis Identifies METTL3-Regulated FGF19 and H6PD as Candidate Targets in Diabetic Cognitive Impairment
Article Snippet: The following antibodies were used in this study: anti-GAPDH (Affinity BiosciencesCincinnati, OH, USA) (1:1000), anti-m6A (Synaptic Systems, Göttingen, Germany, 202003) (for Dot blot:1:1000, for IHC: 1:500), anti-METTL3 (15073-1-AP, Proteintech, Rosemont, Illinois, USA) (for WB:1:2000, for IHC: 1:750), anti-METTL14 (HPA038002, SigmaAldrich, St. Louis, MO, USA) (for WB:1:2000, for IHC: 1:1000), anti-WTAP (60188-1-Ig, Proteintech) (for WB:1:2000, for IHC: 1:500), FTO (27226-1-AP, Proteintech) (for WB:1:1000, for IHC: 1:400), ALKBH5 (16837-1-AP, Proteintech) (for WB:1:2000, for IHC: 1:200), Goat Anti-Mouse IgG H&L (HRP, Affinity Biosciences) (1:10000), Goat Anti-Rabbit IgG H&L (HRP, Affinity Biosciences, Cincinnati, OH, USA) (1:10000), and Goat Anti-Rabbit IgG H&L (Alexa Fluor 488, Abcam, Cambridge, UK) (1:500).



Similar Products

94
Synaptic Systems ihc 1 250

Ihc 1 250, supplied by Synaptic Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc/163+002/pmc13525750-7-2-7
Average 94 stars, based on 1 article reviews
ihc 1 250 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

94
Synaptic Systems ihc 1 200

Ihc 1 200, supplied by Synaptic Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc/163+004/pmc13525750-6-2-8
Average 94 stars, based on 1 article reviews
ihc 1 200 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

95
Synaptic Systems c fos immunostaining

C Fos Immunostaining, supplied by Synaptic Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc/226+004/pm42611930-308-14-24
Average 95 stars, based on 1 article reviews
c fos immunostaining - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

99
ABclonal Biotechnology immunohistochemical staining

Immunohistochemical Staining, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc/Caspase-1+Rabbit+pAb/pm42543667-67-19-38
Average 99 stars, based on 1 article reviews
immunohistochemical staining - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier

93
Proteintech ihc

Ihc, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc/MEOX2+Antibody/pmc12969010-181-1-11
Average 93 stars, based on 1 article reviews
ihc - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

94
Synaptic Systems immunostaining with ankyring
( A ) Representative images of primary branches from WT and Mecp2 HET neurons, treated for 24 hours with cholesterol or with vehicle (0.1 μg/ml), and immunostained for Synapsin1/2 (Syn1/2; green), Shank2 (red) and Map2 (white). Scale bar=5 µm. ( B-D ) Violin plots indicate the median (dashed line) and 25 th and 75 th percentiles (dotted lines) of Synapsin1/2 (B), Shank2 (C) and colocalized puncta number (D). Values for puncta number are expressed as percentages with respect to untreated WT neurons. n=57/69. Statistical analysis was performed by 2-way Anova, followed by Sidak post-hoc test; **p<0.01, ***p<0.001. ( E ) Representative images of axon initial segment (AIS) stained with <t>anti-AnkyrinG</t> (AnkG; red). Scale bar=20 µm. ( F,G ) Violin plots indicate the median (dashed line) and 25 th and 75 th percentiles (dotted lines) of AIS length in WT and Mecp2 HET neurons (at DIV14) after cholesterol supplementation or treated with vehicle (F). The frequency distribution of values of AIS length is shown in (G). n=70/exp.groups. ( H ) Violin plots indicate the median (dashed line) and 25 th and 75 th percentiles (dotted lines) of the distance of AIS from the soma in WT and Mecp2 HET neurons (at DIV14) after cholesterol supplementation or treated with vehicle. n=70/exp.groups. *p<0.05, by 2-way Anova, followed by Sidak post-hoc test;
Immunostaining With Ankyring, supplied by Synaptic Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc/386+005/bio_rxiv__64898__2026__07__29__741426-110-1-5
Average 94 stars, based on 1 article reviews
immunostaining with ankyring - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

93
ABclonal Biotechnology immunohistochemical staining utilized pcna
a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g <t>Immunohistochemical</t> images of tumor sections were examined at 15 days (Ki67 and <t>PCNA,</t> n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.
Immunohistochemical Staining Utilized Pcna, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc/PCNA+Mouse+mAb/pmc13526793-823-0-8
Average 93 stars, based on 1 article reviews
immunohistochemical staining utilized pcna - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

95
ABclonal Biotechnology ihc staining for ki67
a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g <t>Immunohistochemical</t> images of tumor sections were examined at 15 days (Ki67 and <t>PCNA,</t> n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.
Ihc Staining For Ki67, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc/Ki67+Rabbit+mAb/10__1016_slash_j__cej__2026__180066-117-17-24
Average 95 stars, based on 1 article reviews
ihc staining for ki67 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

94
RayBiotech inc cd8
Combination drug treatment decreases tumor growth and increases plasma cytokine levels in humanized mice. A. Schematic representation of generation of humanized mice with a functioning immune system. B. Flow cytometry showing CD45, CD3, CD56, CD14, and CD16 expression in mice peripheral blood. C. Mice imaging showing tumor burden fifteen days after post treatment with DAC (0.01 mg/kg), C92 (30 mg/kg) and combination. D. Photon intensity on the whole mouse body fifteen days after post treatment with DAC (0.01 mg/kg), C92 (30 mg/kg) and combination. E. Mice body weight fifteen days after post treatment with DAC (0.01 mg/kg), C92 (30 mg/kg) and combination. F-H . Cytokine expression of F. TNFα, G. IFNγ, and H. CXCL10 respectively assessed by ELISA assay in plasma from retroorbital bleeds of euthanized mice 15 days after DAC (0.01 mg/kg), C92 (30 mg/kg), and combination treatment. I-J. Immunohistochemistry performed on spleen tissue showing I. CXCL10 cytokines and J. <t>CD8</t> T cell infiltration respectively 15 days after DAC, C92, and combination treatment. K. Graphical model showing Necroptosis pathway activation by DAC and C92 STING agonist combination therapy in AML cells depleted of TP53. DAC and C92 combination therapy demonstrate increased TP53 independent STING pathway that leads to interferon transcription and triggers a ZNFX1-ZBP1 PANoptosis cell death pathway. Activated ZBP1 along with RIPK3 and MLKL phosphorylation are key features of necroptosis, with membrane rupture occurring as a part of this cell death pathway. In cell lines where ZNFX1 is depleted, ZBP1 is completely abrogated and necroptosis does not occur. All data are presented as mean +/- SEM with p-values derived from two-tailed unpaired Student’s t test or ANOVA as appropriate. * p<0.05, p<0.01, p<0.001, p<0.0001. All experiments were performed at least 3 times.
Cd8, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc/Mouse+anti-Human+CD8+Antibody+%5BIHC+only%5D/bio_rxiv__64898__2026__07__27__741029-95-53-60
Average 94 stars, based on 1 article reviews
cd8 - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier

96
Miltenyi Biotec immunostaining for glast
Combination drug treatment decreases tumor growth and increases plasma cytokine levels in humanized mice. A. Schematic representation of generation of humanized mice with a functioning immune system. B. Flow cytometry showing CD45, CD3, CD56, CD14, and CD16 expression in mice peripheral blood. C. Mice imaging showing tumor burden fifteen days after post treatment with DAC (0.01 mg/kg), C92 (30 mg/kg) and combination. D. Photon intensity on the whole mouse body fifteen days after post treatment with DAC (0.01 mg/kg), C92 (30 mg/kg) and combination. E. Mice body weight fifteen days after post treatment with DAC (0.01 mg/kg), C92 (30 mg/kg) and combination. F-H . Cytokine expression of F. TNFα, G. IFNγ, and H. CXCL10 respectively assessed by ELISA assay in plasma from retroorbital bleeds of euthanized mice 15 days after DAC (0.01 mg/kg), C92 (30 mg/kg), and combination treatment. I-J. Immunohistochemistry performed on spleen tissue showing I. CXCL10 cytokines and J. <t>CD8</t> T cell infiltration respectively 15 days after DAC, C92, and combination treatment. K. Graphical model showing Necroptosis pathway activation by DAC and C92 STING agonist combination therapy in AML cells depleted of TP53. DAC and C92 combination therapy demonstrate increased TP53 independent STING pathway that leads to interferon transcription and triggers a ZNFX1-ZBP1 PANoptosis cell death pathway. Activated ZBP1 along with RIPK3 and MLKL phosphorylation are key features of necroptosis, with membrane rupture occurring as a part of this cell death pathway. In cell lines where ZNFX1 is depleted, ZBP1 is completely abrogated and necroptosis does not occur. All data are presented as mean +/- SEM with p-values derived from two-tailed unpaired Student’s t test or ANOVA as appropriate. * p<0.05, p<0.01, p<0.001, p<0.0001. All experiments were performed at least 3 times.
Immunostaining For Glast, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ihc/GLAST+(ACSA-1)+Antibody%2C+anti-human%2Fmouse%2Frat/pmc13401733-138-31-38
Average 96 stars, based on 1 article reviews
immunostaining for glast - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier

Image Search Results


Journal: The Journal of Comparative Neurology

Article Title: The Molecular Architecture of Somatic Spines of the Lateral Septum

doi: 10.1002/cne.70195

Figure Lengend Snippet:

Article Snippet: Synaptopodin , IHC: 1:250 , Rabbit , Synaptic Systems , 163002.

Techniques:

Journal: The Journal of Comparative Neurology

Article Title: The Molecular Architecture of Somatic Spines of the Lateral Septum

doi: 10.1002/cne.70195

Figure Lengend Snippet:

Article Snippet: Synaptopodin , IHC: 1:200 , Guinea pig , Synaptic Systems , 163004.

Techniques:

( A ) Representative images of primary branches from WT and Mecp2 HET neurons, treated for 24 hours with cholesterol or with vehicle (0.1 μg/ml), and immunostained for Synapsin1/2 (Syn1/2; green), Shank2 (red) and Map2 (white). Scale bar=5 µm. ( B-D ) Violin plots indicate the median (dashed line) and 25 th and 75 th percentiles (dotted lines) of Synapsin1/2 (B), Shank2 (C) and colocalized puncta number (D). Values for puncta number are expressed as percentages with respect to untreated WT neurons. n=57/69. Statistical analysis was performed by 2-way Anova, followed by Sidak post-hoc test; **p<0.01, ***p<0.001. ( E ) Representative images of axon initial segment (AIS) stained with anti-AnkyrinG (AnkG; red). Scale bar=20 µm. ( F,G ) Violin plots indicate the median (dashed line) and 25 th and 75 th percentiles (dotted lines) of AIS length in WT and Mecp2 HET neurons (at DIV14) after cholesterol supplementation or treated with vehicle (F). The frequency distribution of values of AIS length is shown in (G). n=70/exp.groups. ( H ) Violin plots indicate the median (dashed line) and 25 th and 75 th percentiles (dotted lines) of the distance of AIS from the soma in WT and Mecp2 HET neurons (at DIV14) after cholesterol supplementation or treated with vehicle. n=70/exp.groups. *p<0.05, by 2-way Anova, followed by Sidak post-hoc test;

Journal: bioRxiv

Article Title: Impaired astrocyte-to-neuron cholesterol trafficking drives synaptic dysfunction in Rett syndrome

doi: 10.64898/2026.07.29.741426

Figure Lengend Snippet: ( A ) Representative images of primary branches from WT and Mecp2 HET neurons, treated for 24 hours with cholesterol or with vehicle (0.1 μg/ml), and immunostained for Synapsin1/2 (Syn1/2; green), Shank2 (red) and Map2 (white). Scale bar=5 µm. ( B-D ) Violin plots indicate the median (dashed line) and 25 th and 75 th percentiles (dotted lines) of Synapsin1/2 (B), Shank2 (C) and colocalized puncta number (D). Values for puncta number are expressed as percentages with respect to untreated WT neurons. n=57/69. Statistical analysis was performed by 2-way Anova, followed by Sidak post-hoc test; **p<0.01, ***p<0.001. ( E ) Representative images of axon initial segment (AIS) stained with anti-AnkyrinG (AnkG; red). Scale bar=20 µm. ( F,G ) Violin plots indicate the median (dashed line) and 25 th and 75 th percentiles (dotted lines) of AIS length in WT and Mecp2 HET neurons (at DIV14) after cholesterol supplementation or treated with vehicle (F). The frequency distribution of values of AIS length is shown in (G). n=70/exp.groups. ( H ) Violin plots indicate the median (dashed line) and 25 th and 75 th percentiles (dotted lines) of the distance of AIS from the soma in WT and Mecp2 HET neurons (at DIV14) after cholesterol supplementation or treated with vehicle. n=70/exp.groups. *p<0.05, by 2-way Anova, followed by Sidak post-hoc test;

Article Snippet: An immunostaining with AnkyrinG (#386005, Synaptic System; 1:1000) was performed to detect axon initial segment (AIS) in cortical neurons.

Techniques: Staining

a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g Immunohistochemical images of tumor sections were examined at 15 days (Ki67 and PCNA, n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.

Journal: Nature Communications

Article Title: Low-intensity pulsed ultrasound-mediated nose-to-brain co-delivery of β-blockers and aPD-L1 enhances glioblastoma immunotherapy

doi: 10.1038/s41467-026-76103-4

Figure Lengend Snippet: a was created by Figdraw. a , b Treatment schedule of the GL261 mouse brain tumor model (by figdraw.com). The detailed treatment sequence and time points. c , d Brain images of each group of mice obtained by T2 magnetic resonance imaging (MRI) with different treatments, where tumors are circled in white dashed lines. e-g Immunohistochemical images of tumor sections were examined at 15 days (Ki67 and PCNA, n = 5). h Survival curves of GBM tumor-bearing mice in different treatment groups ( n = 10). Survival analysis was calculated using the log-rank test. i Body weight changes of GBM tumor-bearing mice in different treatment groups ( n = 10). j , k Evaluation of antitumor effects of different treatments. n = 5 samples per group for data in ( c-f ) and ( i-k ). Data are expressed as the mean ± SD. Statistical significances were determined using one-way ANOVA with Fisher’s LSD post‑hoc test. Comparisons were performed between different groups in ( c-f ) and ( i-k ). Not significant (NS) is P ≥ 0.05, and significant P values are shown. n = 10 samples per group for data in ( h ). Survival analysis was compared using the log-rank test. Source data are provided as a file.

Article Snippet: Immunohistochemical staining utilized PCNA (AC058, PCNA Mouse mAb, Abclonal) and Ki67 (A26755PM, Ki67 Rabbit PolymAb®, Abclonal) antibodies, with technical assistance from Nanjing Youmeng Biotechnology Co., Ltd. Tumor sections underwent immunofluorescence staining using a TUNEL assay kit (Beyotime Biotech, Shanghai, China).

Techniques: Sequencing, Magnetic Resonance Imaging, Immunohistochemical staining

Combination drug treatment decreases tumor growth and increases plasma cytokine levels in humanized mice. A. Schematic representation of generation of humanized mice with a functioning immune system. B. Flow cytometry showing CD45, CD3, CD56, CD14, and CD16 expression in mice peripheral blood. C. Mice imaging showing tumor burden fifteen days after post treatment with DAC (0.01 mg/kg), C92 (30 mg/kg) and combination. D. Photon intensity on the whole mouse body fifteen days after post treatment with DAC (0.01 mg/kg), C92 (30 mg/kg) and combination. E. Mice body weight fifteen days after post treatment with DAC (0.01 mg/kg), C92 (30 mg/kg) and combination. F-H . Cytokine expression of F. TNFα, G. IFNγ, and H. CXCL10 respectively assessed by ELISA assay in plasma from retroorbital bleeds of euthanized mice 15 days after DAC (0.01 mg/kg), C92 (30 mg/kg), and combination treatment. I-J. Immunohistochemistry performed on spleen tissue showing I. CXCL10 cytokines and J. CD8 T cell infiltration respectively 15 days after DAC, C92, and combination treatment. K. Graphical model showing Necroptosis pathway activation by DAC and C92 STING agonist combination therapy in AML cells depleted of TP53. DAC and C92 combination therapy demonstrate increased TP53 independent STING pathway that leads to interferon transcription and triggers a ZNFX1-ZBP1 PANoptosis cell death pathway. Activated ZBP1 along with RIPK3 and MLKL phosphorylation are key features of necroptosis, with membrane rupture occurring as a part of this cell death pathway. In cell lines where ZNFX1 is depleted, ZBP1 is completely abrogated and necroptosis does not occur. All data are presented as mean +/- SEM with p-values derived from two-tailed unpaired Student’s t test or ANOVA as appropriate. * p<0.05, p<0.01, p<0.001, p<0.0001. All experiments were performed at least 3 times.

Journal: bioRxiv

Article Title: STING agonists in combination with epigenetic drugs potentiate ZNFX1-driven inflammatory necroptosis in TP53 -mutated AML

doi: 10.64898/2026.07.27.741029

Figure Lengend Snippet: Combination drug treatment decreases tumor growth and increases plasma cytokine levels in humanized mice. A. Schematic representation of generation of humanized mice with a functioning immune system. B. Flow cytometry showing CD45, CD3, CD56, CD14, and CD16 expression in mice peripheral blood. C. Mice imaging showing tumor burden fifteen days after post treatment with DAC (0.01 mg/kg), C92 (30 mg/kg) and combination. D. Photon intensity on the whole mouse body fifteen days after post treatment with DAC (0.01 mg/kg), C92 (30 mg/kg) and combination. E. Mice body weight fifteen days after post treatment with DAC (0.01 mg/kg), C92 (30 mg/kg) and combination. F-H . Cytokine expression of F. TNFα, G. IFNγ, and H. CXCL10 respectively assessed by ELISA assay in plasma from retroorbital bleeds of euthanized mice 15 days after DAC (0.01 mg/kg), C92 (30 mg/kg), and combination treatment. I-J. Immunohistochemistry performed on spleen tissue showing I. CXCL10 cytokines and J. CD8 T cell infiltration respectively 15 days after DAC, C92, and combination treatment. K. Graphical model showing Necroptosis pathway activation by DAC and C92 STING agonist combination therapy in AML cells depleted of TP53. DAC and C92 combination therapy demonstrate increased TP53 independent STING pathway that leads to interferon transcription and triggers a ZNFX1-ZBP1 PANoptosis cell death pathway. Activated ZBP1 along with RIPK3 and MLKL phosphorylation are key features of necroptosis, with membrane rupture occurring as a part of this cell death pathway. In cell lines where ZNFX1 is depleted, ZBP1 is completely abrogated and necroptosis does not occur. All data are presented as mean +/- SEM with p-values derived from two-tailed unpaired Student’s t test or ANOVA as appropriate. * p<0.05, p<0.01, p<0.001, p<0.0001. All experiments were performed at least 3 times.

Article Snippet: Briefly, sections (5 μm) were deparaffinized, endogenous peroxidase was inactivated in 3% peroxide for 10 min, and antigen retrieval in 0.1 M sodium citrate was performed in a pressure cooker before the sections were blocked with 5% BSA and incubated overnight at 4 °C with polyclonal antibodies against CXCL10/IP-10 (Cat# 10937-1-AP, RRID:AB_2088002) and CD8 (Mouse anti-Human CD8 Antibody, Cat# 188-10258-IHC, RayBiotech, RRID:AB_2857849).

Techniques: Clinical Proteomics, Flow Cytometry, Expressing, Imaging, Enzyme-linked Immunosorbent Assay, Immunohistochemistry, Activation Assay, Phospho-proteomics, Membrane, Derivative Assay, Two Tailed Test